Mankind Pharma Ltd Hits Intraday High with Strong 3.2% Surge

Intraday Trading Highlights

On the day, Mankind Pharma Ltd recorded a gain of 3.2%, outperforming its Pharmaceuticals & Biotechnology sector by 2.69%. The stock’s upward momentum was evident as it traded above its 5-day, 20-day, and 50-day moving averages, signalling short to medium-term strength. However, it remained below its 100-day and 200-day moving averages, indicating some longer-term resistance levels yet to be breached.

The stock’s intraday high of Rs 2,320.35 represented a 3.5% rise, reflecting strong buying interest during the trading session. This surge contributed to the stock’s consecutive gains, with a two-day return of 5.59%, underscoring a sustained positive trend over recent sessions.

Market Context and Sector Comparison

The broader market environment on 7 Jan 2026 was mixed. The Sensex opened lower at 84,620.40, down 442.94 points or 0.52%, and was trading at 84,797.01 by mid-session, still down 0.31%. Despite this, the index remained close to its 52-week high of 86,159.02, just 1.61% away, suggesting underlying resilience in the market.

Mid-cap stocks led the market rally, with the BSE Mid Cap index gaining 0.3%, while Mankind Pharma Ltd’s outperformance against the Sensex highlighted its relative strength within the Pharmaceuticals & Biotechnology sector. The sector itself showed mixed performance, with Mankind Pharma Ltd standing out as a notable intraday gainer.

Performance Metrics and Moving Averages

Examining the stock’s moving averages provides insight into its technical positioning. Mankind Pharma Ltd’s price currently exceeds its 5-day, 20-day, and 50-day moving averages, which often serve as short-term support levels for traders. This alignment suggests positive momentum in recent weeks.

Conversely, the stock remains below its 100-day and 200-day moving averages, which are typically viewed as longer-term trend indicators. This positioning indicates that while the stock is showing strength in the short term, it has yet to overcome longer-term resistance zones that could define its medium to long-term trajectory.

In comparison, the Sensex is trading below its 50-day moving average, although the 50-day average itself is above the 200-day average, signalling a cautiously optimistic market trend overall.

Relative Returns Over Various Timeframes

Mankind Pharma Ltd’s recent returns have outpaced the Sensex across multiple short-term periods. The stock posted a 3.40% gain over one day versus the Sensex’s decline of 0.31%. Over one week, the stock rose 5.54%, while the Sensex fell 0.50%. Similarly, the one-month return for Mankind Pharma Ltd was 5.14%, outperforming the Sensex’s 1.07% decline.

However, over the three-month period, the stock declined by 6.61%, contrasting with the Sensex’s 3.50% gain. The one-year performance shows a more pronounced divergence, with Mankind Pharma Ltd down 20.58% against the Sensex’s 8.44% rise. Year-to-date, the stock has gained 5.54%, while the Sensex has fallen 0.50%.

Longer-term returns over three, five, and ten years show no change for Mankind Pharma Ltd, while the Sensex has delivered substantial gains of 41.56%, 76.32%, and 241.21% respectively, reflecting broader market growth trends.

Mojo Score and Rating Update

Mankind Pharma Ltd currently holds a Mojo Score of 44.0, with a Mojo Grade of Sell, reflecting a downgrade from its previous Hold rating as of 19 Nov 2025. The Market Cap Grade stands at 1, indicating a relatively small market capitalisation within its sector.

This rating adjustment suggests a cautious stance based on the company’s recent performance metrics and market positioning, despite the strong intraday gains observed on 7 Jan 2026.

Summary of Trading Action

The stock’s strong intraday performance on 7 Jan 2026, marked by a 3.5% rise to Rs 2,320.35, highlights notable buying interest and momentum within the Pharmaceuticals & Biotechnology sector. This surge occurred despite a broadly weaker Sensex, underscoring Mankind Pharma Ltd’s relative strength in the current market environment.

Trading above key short-term moving averages while remaining below longer-term averages suggests a stock in transition, with recent gains potentially setting the stage for further technical developments. The consecutive two-day gain of 5.59% reinforces this positive short-term trend.

Investors and market participants will likely continue to monitor the stock’s price action in relation to its moving averages and sector performance to gauge the sustainability of this momentum.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →